27 July, 2015 by The TZ Newswire Staff Comments Off on 3 Questions for National Oilwell Varco When It Reports Earnings
3 Questions for National Oilwell Varco When It Reports Earnings
These three areas will give a decent indication as to whether National Oilwell Varco is weathering the storm.
27 July, 2015 by The TZ Newswire Staff Comments Off on Why these stocks are stuck in a rut
Why these stocks are stuck in a rut
Small-cap stocks have largely outperformed the S&P this year, but now they’re getting hit hard.
27 July, 2015 by The TZ Newswire Staff Comments Off on The Wall Street Journal: Teva to buy Allergan generics for $40.5 billion
The Wall Street Journal: Teva to buy Allergan generics for $40.5 billion
Teva Pharmaceutical agrees to buy Allergan PLC’s generics business for in a deal valued at $40.5 billion, making it one of the world’s biggest drugmakers, and allowing it to drop its bid for Mylan NV.
read more
27 July, 2015 by The TZ Newswire Staff Comments Off on McGraw Hill to buy SNL Financial for about $2.225B
McGraw Hill to buy SNL Financial for about $2.225B
McGraw Hill Financial announced plans to acquire SNL Financial in a cash deal valued at approximately $2.225 billion.
27 July, 2015 by The TZ Newswire Staff Comments Off on What’s fueling the frenzy in China stocks?
What’s fueling the frenzy in China stocks?
Chinese shares slid 8.5 percent on Monday, indicating no reprieve to the violent selling rocking the country’s equity market.
27 July, 2015 by The TZ Newswire Staff Comments Off on EU and IMF mission heads to arrive in Athens by Friday
EU and IMF mission heads to arrive in Athens by Friday
Further to Ryan’s earlier post
here
27 July, 2015 by The TZ Newswire Staff Comments Off on Teva to buy Allergan generic drug business for $40.5 billion
Teva to buy Allergan generic drug business for $40.5 billion
Teva Pharmaceutical Industries (TEVA.TA) has agreed to buy Allergan Plc’s (AGN.N) generic drugs business for $40.5 billion in a deal that will turn Teva into one of the top 10 pharmaceutical companies. The acquisition should help Israel-based Teva, already the world’s largest generic drugmaker, boost growth at a time its top drug, multiple sclerosis treatment Coxaprone, is facing competition.